962 related articles for article (PubMed ID: 28833869)
81. Toward a Smaller Design for EQ-5D-5L Valuation Studies.
Yang Z; Luo N; Oppe M; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Nov; 22(11):1295-1302. PubMed ID: 31708067
[TBL] [Abstract][Full Text] [Related]
82. Public versus patient health preferences: protocol for a study to elicit EQ-5D-5L health state valuations for patients who have survived a stay in intensive care.
Halling CMB; Gudex C; Perner A; Jensen CE; Gyrd-Hansen D
BMJ Open; 2022 May; 12(5):e058500. PubMed ID: 35613809
[TBL] [Abstract][Full Text] [Related]
83. EQ-5D-Y Value Set for Slovenia.
Prevolnik Rupel V; Ogorevc M;
Pharmacoeconomics; 2021 Apr; 39(4):463-471. PubMed ID: 33565048
[TBL] [Abstract][Full Text] [Related]
84. The EQ-5D-5L Improves on the EQ-5D-3L for Health-related Quality-of-life Assessment in Patients Undergoing Total Hip Arthroplasty.
Greene ME; Rader KA; Garellick G; Malchau H; Freiberg AA; Rolfson O
Clin Orthop Relat Res; 2015 Nov; 473(11):3383-90. PubMed ID: 25488404
[TBL] [Abstract][Full Text] [Related]
85. Do Chinese have similar health-state preferences? A comparison of mainland Chinese and Singaporean Chinese.
Wang P; Li MH; Liu GG; Thumboo J; Luo N
Eur J Health Econ; 2015 Nov; 16(8):857-63. PubMed ID: 25260384
[TBL] [Abstract][Full Text] [Related]
86. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis.
Yfantopoulos J; Chantzaras A; Kontodimas S
Arch Dermatol Res; 2017 Jul; 309(5):357-370. PubMed ID: 28528371
[TBL] [Abstract][Full Text] [Related]
87. Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L.
Wong EL; Cheung AW; Wong AY; Xu RH; Ramos-Goñi JM; Rivero-Arias O
Value Health; 2019 Aug; 22(8):916-924. PubMed ID: 31426933
[TBL] [Abstract][Full Text] [Related]
88. 3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set.
Thomas S; Johnson JA; Xie F
Qual Life Res; 2020 Nov; 29(11):3109-3118. PubMed ID: 32705459
[TBL] [Abstract][Full Text] [Related]
89. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
[TBL] [Abstract][Full Text] [Related]
90. Estimating an EQ-5D-3L Value Set for Romania Using Time Trade-Off.
Paveliu MS; Olariu E; Caplescu R; Oluboyede Y; Niculescu-Aron IG; Ernu S; Vale L
Int J Environ Res Public Health; 2021 Jul; 18(14):. PubMed ID: 34299864
[TBL] [Abstract][Full Text] [Related]
91. EQ-5D-5L Slovenian population norms.
Prevolnik Rupel V; Ogorevc M
Health Qual Life Outcomes; 2020 Oct; 18(1):333. PubMed ID: 33028345
[TBL] [Abstract][Full Text] [Related]
92. Valuation of Health States Considered to Be Worse Than Death-An Analysis of Composite Time Trade-Off Data From 5 EQ-5D-5L Valuation Studies.
Gandhi M; Rand K; Luo N
Value Health; 2019 Mar; 22(3):370-376. PubMed ID: 30832976
[TBL] [Abstract][Full Text] [Related]
93. Valuation of EQ-5D-5L health states: a comparison of seven Asian populations.
Wang P; Liu GG; Jo MW; Purba FD; Yang Z; Gandhi M; Pattanaphesaj J; Ahn J; Wong EL; Shafie AA; Busschbach JJ; Luo N
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):445-451. PubMed ID: 30523723
[No Abstract] [Full Text] [Related]
94. Investigating the relative value of health and social care related quality of life using a discrete choice experiment.
Mulhern B; Norman R; De Abreu Lourenco R; Malley J; Street D; Viney R
Soc Sci Med; 2019 Jul; 233():28-37. PubMed ID: 31153085
[TBL] [Abstract][Full Text] [Related]
95. A French Value Set for the EQ-5D-5L.
Andrade LF; Ludwig K; Goni JMR; Oppe M; de Pouvourville G
Pharmacoeconomics; 2020 Apr; 38(4):413-425. PubMed ID: 31912325
[TBL] [Abstract][Full Text] [Related]
96. Value Set for the EQ-5D-Y-3L in Hungary.
Rencz F; Ruzsa G; Bató A; Yang Z; Finch AP; Brodszky V
Pharmacoeconomics; 2022 Dec; 40(Suppl 2):205-215. PubMed ID: 36123448
[TBL] [Abstract][Full Text] [Related]
97. Comparing responsiveness of the EQ-5D-5L, EQ-5D-3L and EQ VAS in stroke patients.
Golicki D; Niewada M; Karlińska A; Buczek J; Kobayashi A; Janssen MF; Pickard AS
Qual Life Res; 2015 Jun; 24(6):1555-63. PubMed ID: 25425288
[TBL] [Abstract][Full Text] [Related]
98. Exploring the importance of controlling heteroskedasticity and heterogeneity in health valuation: a case study on Dutch EQ-5D-5L.
Karim S; Craig BM; Groothuis-Oudshoorn CGM
Health Qual Life Outcomes; 2022 May; 20(1):85. PubMed ID: 35614472
[TBL] [Abstract][Full Text] [Related]
99. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients.
Poór AK; Rencz F; Brodszky V; Gulácsi L; Beretzky Z; Hidvégi B; Holló P; Kárpáti S; Péntek M
Qual Life Res; 2017 Dec; 26(12):3409-3419. PubMed ID: 28875430
[TBL] [Abstract][Full Text] [Related]
100. Valuation Survey of EQ-5D-Y Based on the International Common Protocol: Development of a Value Set in Japan.
Shiroiwa T; Ikeda S; Noto S; Fukuda T; Stolk E
Med Decis Making; 2021 Jul; 41(5):597-606. PubMed ID: 33754886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
